Trial Profile
Intravitreal Aflibercept as Indicated by Real-Time Objective Imaging to Achieve Diabetic Retinopathy Improvement
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary)
- Indications Diabetic retinopathy
- Focus Adverse reactions
- 19 May 2021 Status changed from active, no longer recruiting to completed.
- 03 Feb 2020 Planned End Date changed from 1 Mar 2020 to 1 Apr 2021.
- 03 Feb 2020 Planned primary completion date changed from 1 Dec 2019 to 1 Apr 2021.